retatrutide phase 3 trial results maximum dose clinical trials 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking Triple hormone receptor agonist retatrutide

Efficacy and safety of lixisenatide once-daily versus exenatide twice-daily in patients with type 2 diabetes insufficiently controlled on metformin (GetGoal-X) [abstract 786]

REFERENCES: Kevin Kargman, Semaglutide and Blood Clots: What You Need to Know for Safety and Health, May 29, 2024 Yaqin Zhang, Ruofei Chen, Yangyang Jia, Mingwei Chen, Zongwen Shuai, Effects of Exenatide on Coagulation and Platelet Aggregation in Patients with Type 2 Diabetes, Drug Des Devel Ther 2021 Jul 12;15:30273040 " Ingram, I., GLP-1 Drugs Tied to Reduced Risk of Dangerous Blood Clots, MedPage TodayDecember 8, 2024, ABSTRACT: Patell R "Glucagon-like peptide 1 receptor agonists reduce the risk of venous thromboembolism in patients with diabetes irrespective of obesity: a propensity score-matched multicenter database analysis" ASH 2024

As an example, in mice, prolonged GIP receptor activation improves cognitive function by an increased recognition index (109)

Esto mejorara la composicin corporal, adems de la resistencia y la recuperacin muscular